MaxCyte Inc MYE0
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.22
- Day Range
- $4.22–4.22
- 52-Week Range
- $2.50–14.20
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $441.18 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.77
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 143
- Website
- https://www.maxcyte.com
Comparables
Valuation
|
Metric
|
MYE0
|
PTGX
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 12.60 | — |
Price/Book Value | 2.10 | 3.21 | 5.43 |
Price/Sales | 10.77 | 5.86 | 19.05 |
Price/Cash Flow | — | 9.63 | 373.37 |
Price/Earnings
MYE0
PTGX
ACLX
Financial Strength
|
Metric
|
MYE0
|
PTGX
|
ACLX
|
|---|---|---|---|
Quick Ratio | 12.13 | 15.61 | 5.32 |
Current Ratio | 13.26 | 15.72 | 5.46 |
Interest Coverage | — | — | −22.10 |
Quick Ratio
MYE0
PTGX
ACLX
Profitability
|
Metric
|
MYE0
|
PTGX
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −8.38% | 51.28% | −1.99% |
Return on Equity (Normalized) | −9.55% | 56.32% | −3.75% |
Return on Invested Capital (Normalized) | −13.18% | 51.24% | −7.24% |
Return on Assets
MYE0
PTGX
ACLX
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Ggpgtgfz | Wbcjk | $181.1 Bil | |
SYK
| Stryker Corp | Szsmgdmms | Mql | $127.5 Bil | |
MDT
| Medtronic PLC | Pddhsxy | Qhrqzq | $113.7 Bil | |
BSX
| Boston Scientific Corp | Bbdzqhb | Kjxfwfn | $109.6 Bil | |
EW
| Edwards Lifesciences Corp | Fpbrfkktjc | Kkjmdx | $54.3 Bil | |
DXCM
| DexCom Inc | Whqswwhtk | Qqvq | $52.0 Bil | |
PHG
| Koninklijke Philips NV ADR | Khcgnwcn | Lkkdxsg | $26.4 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Nlnprjzx | Kxfnf | $24.7 Bil | |
ALGN
| Align Technology Inc | Qhjylmjhg | Xnshkx | $20.6 Bil | |
PODD
| Insulet Corp | Rvxqnmvhw | Jcgrdf | $13.1 Bil |